TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27852708
Drug: Daily diaries
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily diaries
Study: 29332235
Drug: Weekly diaries
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly diaries
Study: 29332235
Drug: Weekly automated
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly automated feedback
Study: 25515244
Drug: 1% squalamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% squalamine ointment
Study: 21416311
Drug: Dexmedetomidine IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine IV (0.5 μg/kg bolus over 10 min and 0.5 μg/kg/h infusion) with local anesthesia (lidocaine 2% with epinephrine)
Study: 21416311
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia (15 ml of 0.25% bupivacaine + 100 μg fentanyl)
Study: 16012523
Drug: Concurrent combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent combination chemotherapy and radiotherapy (66 Gy in 33 fractions)
Study: 16012523
Drug: Concurrent combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent combination chemotherapy and radiotherapy
Study: 10365740
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Dalteparin)
Study: 7486898
Drug: Coca-Cola Classic
Normalized name: cola extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coca-Cola Classic (240 ml) with ketoconazole (200 mg)
Study: 7486898
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with ketoconazole (200 mg) (control)
Study: 7486898
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with ketoconazole (200 mg) after omeprazole (60 mg)
Study: 6262930
Drug: Cefazoline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazoline (1 gram) administered 30 minutes before operation
Study: 21509053
Drug: Sublingual nitroglycerine
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerine (NEDV)
Study: 17103167
Drug: Neoadjuvant radio-chemotherapy
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant radio-chemotherapy (NARCT)
Study: 9158268
Drug: Imipramine (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (0.9 mg/kg for three weeks)
Study: 7689205
Drug: Sotalol (2.0‐2.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (2.0‐2.9 mg/kg)
Study: 7689205
Drug: Flecainide (2.5‐3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (2.5‐3.3 mg/kg)
Study: 7689205
Drug: Verapamil (3.3‐3.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (3.3‐3.7 mg/kg)
Study: 18475293
Drug: Paclitaxel poliglumex
Normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel poliglumex (PPX) 175 mg m(‐2)
Study: 18475293
Drug: Paclitaxel poliglumex
Normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel poliglumex (PPX) 210 mg m(‐2)
Study: 18475293
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg m(‐2)
Study: 12355999
Drug: Thiazide‐like diuretic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide‐like diuretic, slow‐release indapamid
Study: 12355999
Drug: Converting enzyme
Normalized name: Prohormone converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Converting enzyme inhibitor, enalapril 20 mg
Study: 10692717
Drug: Sumatriptan 50
Normalized name: sumatriptan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 50 mg tablets
Study: 6416805
Drug: 2% nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% nitroglycerin ointment (2 cm/m2 body surface)
Study: 6416805
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2% nitroglycerin ointment and 50 mg atenolol
Study: 30986326
Drug: Rotary NiTi
Normalized name: Rytary
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rotary NiTi to size 20, .04 taper with syringe and needle (SNI)
Study: 30986326
Drug: Rotary NiTi
Normalized name: Rytary
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rotary NiTi to size 20, .04 taper with ultrasonically activated irrigation (UAI)
Study: 30986326
Drug: Rotary NiTi
Normalized name: Rytary
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rotary NiTi to size 40, .04 taper with syringe and needle (SNI)
Study: 30986326
Drug: Rotary NiTi
Normalized name: Rytary
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rotary NiTi to size 40, .04 taper with ultrasonically activated irrigation (UAI)
Study: 27714530
Drug: Ginger (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (500 mg) twice daily for 5 days starting on the first day of the second AC cycle
Study: 27714530
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 5 days starting on the first day of the second AC cycle
Study: 26045831
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg intravenous injection for 20 min)
Study: 23555741
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of IIV
Study: 23555741
Drug: LAIV-IIV administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LAIV-IIV administration
Study: 21651947
Drug: SII HibP(RO)
Normalized name: phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SII HibP(RO) vaccine manufactured at industrial scale
Study: 21651947
Drug: SII HibP(RO)
Normalized name: phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SII HibP(RO) vaccine manufactured at small scale
Study: 11213940
Drug: Rocuronium bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium bromide infusion at 10 microg/kg/min for 24 to 120 hours after a bolus of 0.6 mg/kg
Study: 11213940
Drug: Rocuronium bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium bromide infusion
Study: 2967665
Drug: Mucopolysaccharide polysulphate
Normalized name: mucopolysaccharide polysulfate
DrugBank: Mucopolysaccharide polysulphate (DB16564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucopolysaccharide polysulphate (MPS) cream applied twice daily
Study: 2967665
Drug: Cream base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream base (control) applied twice daily
Study: 21804130
Drug: torcetrapib plus
Normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: torcetrapib plus atorvastatin
Study: 28974520
Drug: atorvastatin only
Normalized name: Atorvastatin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin only
Study: 27780197
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 200 mg/kg buccal 40% dextrose gel
Study: 12931275
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (0.3 U/kg 125I‐insulin glargine)
Study: 12931275
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (0.3 U/kg 125I‐NPH insulin)
Study: 8617707
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 to 200 mg daily for 10 days)
Study: 8617707
Drug: Carbamazepine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (200 mg once daily for 2 days, then every 12 hours)
Study: 8617707
Drug: Carbamazepine plus
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine plus Sertraline
Study: 31571176
Drug: Intraventricular alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraventricular alteplase injections (n=251)
Study: 31571176
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) injections (n=249)
Study: 30824955
Drug: Doripenem (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doripenem (1.0 g every 8 h)
Study: 30824955
Drug: Meropenem (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1.0 g every 8 h)
Study: 21324135
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose olanzapine LAI (150 mg/2 weeks)
Study: 21324135
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose olanzapine LAI (405 mg/4 weeks)
Study: 21324135
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose olanzapine LAI (300 mg/2 weeks)
Study: 21324135
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose olanzapine LAI
Study: 21324135
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose olanzapine LAI
Study: 21324135
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose olanzapine LAI
Study: 21324135
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of olanzapine LAI
Study: 18852332
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (28 g)
Study: 12791116
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (500 micro g.kg-1 i.v. ketamine preincision and a ketamine infusion at 4 micro g.kg-1 min-1 postoperatively)
Study: 12791116
Drug: Ketamine bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine bolus (500 micro g.kg-1 i.v. ketamine preincision and a saline infusion postoperatively)
Study: 12791116
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline infusion postoperatively)
Study: 23569309
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with paclitaxel/gemcitabine (PG)
Study: 12512035
Drug: Lamivudine treatment
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine treatment for 1 year
Study: 12512035
Drug: Lamivudine treatment
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine treatment for 2 additional years
Study: 12512035
Drug: Lamivudine treatment
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine treatment for 3 years
Study: 1904989
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin therapy at a dose of 400 mg per kilogram every three weeks
Study: 1904989
Drug: No immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immune globulin therapy (Control)
Study: 7046774
Drug: labetalol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol monotherapy (329 mg daily for 12 weeks)
Study: 7046774
Drug: labetalol combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol combined with diuretics (374 mg daily for 12 weeks)
Study: 7046774
Drug: labetalol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol monotherapy (260 mg daily for 6 months or longer)
Study: 7046774
Drug: labetalol combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol combined with diuretics (450 mg daily for 6 months or longer)
Study: 26255456
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg i.v. dissolved in 10 ml 0.9% NaCl
Study: 26255456
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl 10 mg)
Study: 15291907
Drug: Oral desensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desensitization with increasing doses of cow's milk starting from 0.06 mg of CM proteins
Study: 11292409
Drug: Ganciclovir implant
Normalized name: ganciclovir Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir implant plus oral ganciclovir (1 gm three times daily)
Study: 11292409
Drug: Intravenous cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cidofovir (5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week)
Study: 28107143
Drug: Clarithromycin 5
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 5 mg/kg daily for 4 weeks
Study: 18294337
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) + Sulfadoxine/Pyrimethamine (SDx/PYR) combination
Study: 18294337
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of CQ + SDx/PYR
Study: 18294337
Drug: Full-strength CQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-strength CQ + SDx/PYR combination
Study: 14608559
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug and acupressure bands
Study: 14608559
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug and placebo bands
Study: 7745195
Drug: Ice applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice applied to subcutaneous heparin injection sites
Study: 7114515
Drug: Cimetidine (therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (therapy group)
Study: 7114515
Drug: Placebo (therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (therapy group)
Study: 25332474
Drug: Dairy diet
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy diet (3 servings/d: 375 mL low-fat milk, 175 g low-fat yogurt, 30 g regular-fat cheddar cheese)
Study: 23053790
Drug: Total testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total testosterone (ng/mL)
Study: 23053790
Drug: SHBG (nmol/L)
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHBG (nmol/L)
Study: 23053790
Drug: Free estradiol
Normalized name: Free estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free estradiol (fg/mL)
Study: 20173425
Drug: Distributed form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distributed form of constraint‐induced therapy
Study: 18809812
Drug: 25% energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% energy deficit by a combination of CR and increased aerobic exercise (CR + EX group)
Study: 19900349
Drug: Haloperidol (2-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2-40 mg)
Study: 12389342
Drug: Control pediculicide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control pediculicide spray containing permethrin, malathion, piperonyl butoxide, isododecane, and propellant gas; applied twice for 10 minutes with a 10-day interval between applications.
Study: 7605863
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once a day for 2 weeks (Group 1)
Study: 7605863
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once a day for 4 weeks (Group 2)
Study: 7605863
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg twice a day for 2 weeks (Group 3)
Study: 7605863
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg twice a day for 4 weeks (Group 4)
Study: 2194694
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy combined with ticlopidine 250 mg b.i.d. (group C + T)
Study: 26517
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg mequitazine twice daily
Study: 6983839
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg disoprofol
Study: 6983839
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg disoprofol
Study: 3877474
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg thiopentone
Study: 6983839
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg thiopentone
Study: 6983839
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg methohexitone
Study: 22305678
Drug: Pneumovax (23-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumovax (23-valent pneumococcal polysaccharide vaccine)
Study: 20819223
Drug: Manipulative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulative therapy (manipulation and mobilization) in addition to usual medical care (UMC)
Study: 20819223
Drug: Manipulative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulative therapy (manipulation and mobilization)
Study: 16222074
Drug: Repeated thermal
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated thermal stimuli on the same side for five daily sessions (Study 1)
Study: 16222074
Drug: Thermal stimuli
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal stimuli restricted to one side for four daily sessions, then applied to the other side on the fifth session (Study 2)
Study: 14566490
Drug: Single-lumen tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-lumen tube (SLT) with intrathoracic CO2 insufflation at a rate of 0.5-1 l.min(-1) and sustained intrathoracic pressure at 6 mmHg
Study: 10101653
Drug: CT-guided intratumoral
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided intratumoral gene therapy (10 ml of a vector solution with replication-defective adenovirus containing wild-type p53 cDNA)
Study: 10101653
Drug: CT-guided intratumoral
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided intratumoral gene therapy (2 ml aliquots injected into different tumor areas)
Study: 10101653
Drug: CT-guided intratumoral
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided intratumoral gene therapy
Study: 224958
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate or oral fluphenazine
Study: 27275351
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg doxycycline once daily for 30 days
Study: 27275351
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg doxycycline twice daily for 75 days
Study: 16641904
Drug: Chemoradiotherapy (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (docetaxel 20 mg m(‐2) once weekly every 6 weeks + radiotherapy 2 Gy for 5 days a week, total 60 Gy)
Study: 12695290
Drug: Propranolol (beta-blockers)
Normalized name: beta-Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (beta-blockers)
Study: 11063789
Drug: m‐CPP (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: m‐CPP (0.5 mg/kg)
Study: 3530933
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg E2V
Study: 23268187
Drug: 72 hours
Normalized name: PATCH, TRANSDERMAL 72 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72 hours of perioperative antimicrobial therapy
Study: 23268187
Drug: 120 hours
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 hours of perioperative antimicrobial therapy
Study: 18617385
Drug: Hyperbaric ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric ropivacaine 15 mg
Study: 18617385
Drug: Hyperbaric ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric ropivacaine 10 mg with sufentanil 5 micrograms
Study: 10891645
Drug: Ethanol (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.7 g of ethanol/kg body weight)
Study: 6707381
Drug: 1.64 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.64 mg/kg amrinone
Study: 6707381
Drug: amrinone therapy
Normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amrinone therapy
Study: 6707381
Drug: placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo therapy
Study: 6707381
Drug: amrinone re-administration
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: amrinone re-administration
Study: 24946629
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy (electroacupuncture, moxibustion, moving cupping)
Study: 24946629
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (vitamin B1 and mecobalamine)
Study: 22215073
Drug: Transarterial chemoembolisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transarterial chemoembolisation (TACE) with doxorubicin (75, 50, and 25 mg/m² based on bilirubin levels) and lipiodol, combined with continuous sorafenib 800 mg/day
Study: 17392295
Drug: Mood stabilizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood stabilizer plus adjunctive antidepressant therapy
Study: 16123205
Drug: Extravehicular activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extravehicular activity (EVA) with denitrogenation procedures; initial cabin pressure 748 mmHg, final suit pressure approximately 295 or approximately 220 mmHg; no specific dosage or duration mentioned.